Radiopharm Theranostics (RADX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Radiopharm Theranostics (RADX) is Strong Underperform.

The composite score behind that read is -0.54, weighing +0.00 of bullish evidence against -0.53 bearish.

Radiopharm Theranostics last closed at $1.15, -2.54% on the session.

Against the IVW growth benchmark the position is -2.38% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

18 graded predictions for RADX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Radiopharm Theranostics is classified under Health Care / Biotechnology, with a market capitalisation of $18.53M.

StockMap tracks Radiopharm Theranostics as the 336th largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Radiopharm Theranostics ranks 373rd of 377 in the group, against a group median of -0.21.